Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.

[1]  E. Felip,et al.  Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Interim results of the European Erlotinib Versus Chemotherapy (EURTAC) phase III randomized trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[3]  A. Jemal,et al.  Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.

[4]  R. Gutzmer,et al.  Management of the Cutaneous Side Effects of Therapeutic Epidermal Growth Factor Receptor Inhibition , 2010, Oncology Research and Treatment.

[5]  Qinghua Zhou,et al.  Comparisons between the National Comprehensive Cancer Network (NCCN) non‐small‐cell lung cancer (NSCLC) Clinical Practice Guidelines (Chinese version), the NCCN original edition, and the European Society for Medical Oncology NSCLC Guidelines in 2009 , 2010, Thoracic cancer.

[6]  A. Gemma,et al.  F1000 highlights , 2010 .

[7]  G. Giaccone,et al.  Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. , 2010, The Lancet. Oncology.

[8]  P. Jänne,et al.  Randomized phase II trial of erlotinib (E) alone or in combination with carboplatin/paclitaxel (CP) in never or light former smokers with advanced lung adenocarcinoma: CALGB 30406. , 2010 .

[9]  S. Toyooka,et al.  Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. , 2010, The Lancet. Oncology.

[10]  Lin Huan,et al.  Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer , 2010 .

[11]  T. Mok,et al.  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. , 2009, The New England journal of medicine.

[12]  Lesley Seymour,et al.  Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Joon-Oh Park,et al.  Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non small-cell lung cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Edward S. Kim,et al.  Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. , 2007, The oncologist.

[15]  T. Mok,et al.  Epidermal Growth Factor Receptor Mutations and Their Correlation with Gefitinib Therapy in Patients with Non-small Cell Lung Cancer: A Meta-Analysis Based on Updated Individual Patient Data from Six Medical Centers in Mainland China , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[16]  M. Meyerson,et al.  Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  L. Tanoue,et al.  Erlotinib in Previously Treated Non-Small-Cell Lung Cancer , 2007 .

[18]  G. Giaccone,et al.  Erlotinib for Frontline Treatment of Advanced Non–Small Cell Lung Cancer: a Phase II Study , 2006, Clinical Cancer Research.

[19]  Quynh-Thu Le,et al.  Non-small cell lung cancer: Clinical practice guidelines in oncology , 2006 .

[20]  J. Minna,et al.  Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. , 2006, Journal of the National Cancer Institute.

[21]  David Harrington,et al.  Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. , 2002, The New England journal of medicine.